Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.54 |
| ▸ | MMP13 | P45452 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163303 | 0.92 | MMP13 (0.56) | RAB9AMAPTNPC1PTGER1MMP13 | |
| SCHEMBL15602720 | 0.91 | RAB9A (0.53) | RAB9AMAPTNPC1PTGER1MMP13 | |
| SCHEMBL4720405 | 0.87 | PTGER1 (0.74) | RAB9AMAPTNPC1PTGER1MMP13 | |
| SCHEMBL7383666 | 0.87 | MAPT (0.49) | RAB9AMAPTNPC1PTGER1MMP13 | |
| SCHEMBL7381559 | 0.85 | PTGER1 (0.61) | PTGER1MMP13ALDH1A1ACHE | |
| SCHEMBL7167459 | 0.85 | RAB9A (0.53) | RAB9AMAPTNPC1GAAPOLB | |
| SCHEMBL5337599 | 0.84 | RAB9A (0.56) | RAB9AMAPTNPC1GAAPOLB | |
| SCHEMBL30671738 | 0.84 | RAB9A (0.56) | RAB9AMAPTNPC1GAAPOLB | |
| SCHEMBL22939882 | 0.84 | MMP13 (0.62) | RAB9AMAPTNPC1MMP13GAA | |
| SCHEMBL14124905 | 0.84 | RAB9A (0.50) | RAB9AMAPTNPC1PTGER1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0975612-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-06-13 | — | — | EP | claimed |
| EP-0977743-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-02-09 | — | — | EP | claimed |
| EP-0975612-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-02 | — | — | EP | claimed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | claimed |
| WO-1998046582-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-22 | — | — | WO | claimed |
| US-6586466-B2 | Enzyme inhibitor for use in the treatment of bone, oral, arthritic, paget's and hypercalcemic diseases | SMITHKLINE BEECHAM CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-6562842-B2 | Osteoporosis, oral diseases | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020173469-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-11-21 | — | — | US | disclosed |
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | THOMPSON SCOTT KEVIN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020077455-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-06-20 | — | — | US | disclosed |
| CN-1341592-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| US-5998470-A | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1999053039-A1 | TREATMENT OF PARASITIC DISEASES BY INHIBITION OF CYSTEINE PROTEASES OF THE PAPAIN SUPERFAMILY | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| WO-1998049152-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998046582-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156018-A1 | Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily | PEPD, PREP, CPN1 | RAB9A 2225/4885MAPT 2704/4885NPC1 844/4885 |
| US-20020173469-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | RAB9A 1337/4885MAPT 1072/4885NPC1 862/4885 |
| US-20020077455-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | RAB9A 1337/4885MAPT 1072/4885NPC1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.